drugset / Trial / NCT04729062

C3G/Primary IC-MPGN EAP

NCT04729062 ↗

Expanded access Approved for marketing Apellis Pharmaceuticals, Inc.

Summary

This is an Early Access Program (EAP) which will provide access to pegcetacoplan for eligible participants with C3G and Primary IC-MPGN.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegcetacoplan Peptide — —